The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•16 April 2026•

1 min read

Design Therapeutics Hits 52-Week High Following Q4 Earnings Beat

Key Facts

1Design Therapeutics (DSGN) reached a new 52-week high of $12.98.

2The company reported Q4 EPS of ($0.27), exceeding analyst estimates.

3Analysts have an average price target of $15.20 with a 'Moderate Buy' consensus.

Shares of Design Therapeutics (DSGN) surged to a new 52-week high, reaching $12.98 during recent trading sessions. The rally follows the company's Q4 earnings report, which posted an EPS of ($0.27), effectively beating analyst consensus estimates. Investor confidence is further bolstered by significant institutional backing, with institutions holding a 56.64% stake in the biotech firm. Analysts currently maintain a 'Moderate Buy' consensus on the stock, with an average price target of $15.20, suggesting further upside potential. This positive price action reflects the market's reaction to the earnings beat and the company's strengthening financial position. Market participants are now closely watching if the stock can maintain its momentum toward the projected analyst targets.